SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001213900-24-070284
Filing Date
2024-08-16
Accepted
2024-08-16 16:34:29
Documents
4

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D ea0211485-13dciti_citiuson.htm SC 13D 68791
2 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION, DATED AS OF OCTOBER 23, 2023, B ea021148501ex99-1_citius.htm EX-99.1 593992
3 SIDE LETTER AGREEMENT, DATED AS OF AUGUST 12, 2024, BY AND BY AND AMONG CITIUS P ea021148501ex99-2_citius.htm EX-99.2 19741
4 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT, DATED AS OF AUGUST 12, 2024, ea021148501ex99-3_citius.htm EX-99.3 130134
  Complete submission text file 0001213900-24-070284.txt   814627
Mailing Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6676
Citius Pharmaceuticals, Inc. (Filed by) CIK: 0001506251 (see all company filings)

IRS No.: 273425913 | State of Incorp.: NV | Fiscal Year End: 0930
Type: SC 13D
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 420 LEXINGTON AVE, SUITE 2446 NEW YORK NY 10017
Business Address 420 LEXINGTON AVE, SUITE 2446 NEW YORK NY 10017 (347) 627-0058
CITIUS ONCOLOGY, INC. (Subject) CIK: 0001851484 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-93794 | Film No.: 241217172
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)